Anne Altmeyer - Oct 20, 2025 Form 4 Insider Report for Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Role
Director
Signature
/s/ Meghan Houghton, attorney-in-fact for Anne Altmeyer
Stock symbol
CRBP
Transactions as of
Oct 20, 2025
Transactions value $
-$16,642
Form type
4
Date filed
10/21/2025, 04:54 PM
Previous filing
Jun 2, 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Altmeyer Anne Director C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 500 RIVER RIDGE DRIVE, NORWOOD /s/ Meghan Houghton, attorney-in-fact for Anne Altmeyer 2025-10-21 0001947086

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRBP Common Stock, par value $0.0001 per share Options Exercise $5.09K +1.06K +17.12% $4.80 7.25K Oct 20, 2025 Direct F1
transaction CRBP Common Stock, par value $0.0001 per share Sale -$21.7K -1.06K -14.62% $20.50 6.19K Oct 20, 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRBP Stock options (right to buy) Options Exercise $0 -1.06K -19.97% $0.00 4.25K Oct 20, 2025 Common Stock 1.06K $4.80 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This amount includes 4,800 unvested RSUs that were granted on May 30, 2025 and vest 100% on the one-year anniversary of the date of grant.
F2 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2024.
F3 The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan and is fully vested.